Evidence map›Paper›PMID 25411794›Full record

ArticlePLoS genetics2014

Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity.

Eric W Refsland, Judd F Hultquist, Elizabeth M Luengas, Terumasa Ikeda, Nadine M Shaban, Emily K Law, William L Brown, Cavan Reilly, Michael Emerman, Reuben S Harris

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 105 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Fitness Landscapes of APOBEC3G Antagonism by HIV-1 Vif proteins.bioRxiv : the preprint server for biology · 2025
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Molecular Biology and Diversification of Human Retroviruses.Frontiers in virology (Lausanne, Switzerland) · 2022
    Article
  17. Article
  18. Review
  19. Review
  20. Article

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Eric W RefslandDepartment of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota, United States of America; Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota, United States of America; Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota, United States of America; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States of America.
Judd F HultquistDepartment of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota, United States of America; Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota, United States of America; Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota, United States of America; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States of America.
Elizabeth M LuengasDepartment of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota, United States of America; Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota, United States of America; Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota, United States of America; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States of America.
Terumasa IkedaDepartment of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota, United States of America; Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota, United States of America; Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota, United States of America; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States of America.
Nadine M ShabanDepartment of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota, United States of America; Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota, United States of America; Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota, United States of America; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States of America.
Emily K LawDepartment of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota, United States of America; Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota, United States of America; Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota, United States of America; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States of America.
William L BrownDepartment of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota, United States of America; Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota, United States of America; Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota, United States of America; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States of America.
Cavan ReillyInstitute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota, United States of America; Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota, United States of America.
Michael EmermanDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Reuben S HarrisDepartment of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota, United States of America; Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota, United States of America; Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota, United States of America; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States of America.
University of Minnesota · USFred Hutch Cancer Center · US

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Marian Esvelt · 1985 to 2026
$296.4M
Structural Characterization of APOBECS's Atomic interactionsP01GM091743 · NIGMS · UNIVERSITY OF MINNESOTA · PI MATSUO, HIROSHI · 2011 to 2015
$10.1M
VPR AND HIV INFECTIONR01AI030927 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI EMERMAN, MICHAEL · 1991 to 2020
$5.3M
APOBEC3 Proteins in HIV RestrictionR37AI064046 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI HARRIS, REUBEN S · 2015 to 2024
$4.2M
APOBEC proteins and uracil in retrovirus restrictionR01AI064046 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI HARRIS, REUBEN S · 2005 to 2014
$3.0M
DNA deaminases and HIV drug resistanceF31DA033186 · NIDA · UNIVERSITY OF MINNESOTA · PI REFSLAND, ERIC · 2012 to 2014
$66k
NCI NIH HHS P30 CA015704NIAID NIH HHS R01 AI030927NIAID NIH HHS R01 AI064046NIAID NIH HHS R37 AI064046NIDA NIH HHS F31 DA033186NIGMS NIH HHS P01 GM091743
6 · The paper itself

Abstract

The Vif protein of HIV-1 allows virus replication by degrading several members of the host-encoded APOBEC3 family of DNA cytosine deaminases. Polymorphisms in both host APOBEC3 genes and the viral vif gene have the potential to impact the extent of virus replication among individuals. The most genetically diverse of the seven human APOBEC3 genes is APOBEC3H with seven known haplotypes. Overexpression studies have shown that a subset of these variants express stable and active proteins, whereas the others encode proteins with a short half-life and little, if any, antiviral activity. We demonstrate that these stable/unstable phenotypes are an intrinsic property of endogenous APOBEC3H proteins in primary CD4+ T lymphocytes and confer differential resistance to HIV-1 infection in a manner that depends on natural variation in the Vif protein of the infecting virus. HIV-1 with a Vif protein hypo-functional for APOBEC3H degradation, yet fully able to counteract APOBEC3D, APOBEC3F, and APOBEC3G, was susceptible to restriction and hypermutation in stable APOBEC3H expressing lymphocytes, but not in unstable APOBEC3H expressing lymphocytes. In contrast, HIV-1 with hyper-functional Vif counteracted stable APOBEC3H proteins as well as all other endogenous APOBEC3s and replicated to high levels. We also found that APOBEC3H protein levels are induced over 10-fold by infection. Finally, we found that the global distribution of stable/unstable APOBEC3H haplotypes correlates with the distribution a critical hyper/hypo-functional Vif amino acid residue. These data combine to strongly suggest that stable APOBEC3H haplotypes present as in vivo barriers to HIV-1 replication, that Vif is capable of adapting to these restrictive pressures, and that an evolutionary equilibrium has yet to be reached.

Indexed as

AminohydrolasesCD4-Positive T-LymphocytesCell LineHaplotypesHIV-1HIV InfectionsHumansMutationPolymorphism, Geneticvif Gene Products, Human Immunodeficiency VirusVirus ReplicationAminohydrolasesAPOBEC3H protein, humanvif Gene Products, Human Immunodeficiency Virusvif protein, Human immunodeficiency virus 1

Identifiers

PMID25411794
PMCPMC4238949
OpenAlexW2026909045

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.